Takeda’s Zejula poised to change local ovarian cancer treatment market

Korea Biomedical Review

29 July 2019 - Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance benefit, according to the Health Insurance Review and Assessment Service’s pharmaceutical reimbursement evaluation committee. 

The drug is a poly ADP-ribose polymerase (PARP) inhibitor to treat ovarian cancer and gained a local license in March.

Unlike another ovarian cancer drug AstraZeneca’s Lynparza (olaparib), Zejula can be used regardless of BRCA -- breast cancer gene 1, 2 -- mutation. Zejula’s merit can bring a sea change in the domestic ovarian cancer treatment market, experts said.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder